The Gut-lung Axis in Chronic Obstructive Pulmonary Disease

Dynamic Changes of the Respiratory Microbiota and Its Relationship to Fecal Microbiota in Chronic Obstructive Pulmonary Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03236480

Enrollment

100

Registered

2017-08-02

Start date

2017-01-01

Completion date

2019-01-01

Last updated

2017-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunity, Mucosal, Metabolism, Microbiota, Pulmonary Disease, Chronic Obstructive

Brief summary

Patients with chronic obstructive pulmonary disease (COPD) are 2-3 times more likely to occur together with chronic gastrointestinal tract (GIT) diseases, such as inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS). Similarly, despite many patients have no history of acute or chronic respiratory disease, up to 50% of IBD patients and 33% of IBS patients have pulmonary involvement, such as inflammation or impaired lung function. Increasing evidence indicated chronic gut and lung disease share key conceptual features with the disorder and dysregulation of the microbial ecosystem. However, the underlying mechanisms are not well understood. Our study is aimed to elucidate the intimate relationship between the gastrointestinal tract and respiratory tract, and uncover the mechanisms by which the gut microbiota affects the immune responses in the lungs, and vice versa.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* admitted to hospital with an exacerbation of COPD; * with no history of probiotics taken; * the duration of antibiotics treatment before enrollment should be less than 72 hours.

Exclusion criteria

* being immunocompromised, including history of glucocorticoid taken for more than 1 month, history of immunosuppressive therapy, history of human immunodeficiency virus (HIV) infection, solid tumor or hematological malignancy; * history of long-term nursing home stays; * history of recently hospitalized (\<90 days).

Design outcomes

Primary

Measure	Time frame	Description
all-cause mortality	patients will be followed for 3 months after their remission from hospital	all-cause death after the enrollment

Secondary

Measure	Time frame	Description
exacerbations	during the 3-month follow-up	exacerbations of COPD

Countries

China

Contacts

Primary ContactYali Zheng, Dr.

yali_zheng@126.com+8615011451515

Outcome results